We are witnessing one of the most significant shifts in modern healthcare.
On one side, we have increasing medicalisation:
On the other, a growing wave of questioning voices asking:
👉 Are we treating risk… or creating lifelong patients?
The recent push by the American Heart Association and American College of Cardiology to expand cholesterol intervention into people in their 30s has brought this tension into sharp focus.
At the same time, we are seeing:
This raises a critical question:
👉 Are we moving toward better health… or deeper dependency?
For decades, cholesterol has been framed as the enemy.
But biologically, this narrative is incomplete.
Cholesterol is essential for:
As metabolic scientist Benjamin Bikman describes:
👉 “Cholesterol is a molecule of life.”
LDL (low-density lipoprotein) is often labelled “bad cholesterol.”
But the reality is more nuanced.
The real issue is not LDL alone—it’s the environment it operates in:
These conditions lead to oxidised LDL, which contributes to arterial damage.
👉 In other words: the problem is metabolic dysfunction—not cholesterol in isolation.
Here’s where the conversation becomes even more interesting.
Studies of long-lived populations show something unexpected:
👉 Many of the world’s longest-living individuals have higher LDL levels.
Research highlights:
This is often referred to as the “cholesterol paradox.”
It challenges a simplistic narrative.
Longevity appears to be more strongly linked to:
👉 Not just a single cholesterol number.
At the same time cholesterol guidelines are expanding, another phenomenon is reshaping healthcare:
👉 The rise of GLP-1 weight loss drugs.
Medications like:
have transformed weight management.
They work by:
👉 And most importantly:
They do not teach people how to live differently.
Instead of improving food quality…
Major corporations are now introducing:
👉 “GLP-1 Friendly” food labels
Companies like Nestlé and Conagra Brands are targeting drug users.
Here’s the problem:
👉 It’s marketing—not medicine.
If food had been:
We may never have needed:
The real drivers of chronic disease are becoming clearer:
These are rarely the primary focus of mainstream interventions.
👉 Because they are harder to medicate.
But they are highly responsive to:
Long before prescriptions, humans relied on something far more powerful:
👉 Nature
Evidence-backed benefits include:
👉 These are not “alternative therapies”
They are biological necessities.
This is where your positioning becomes incredibly powerful, Partner.
Because what this entire discussion reveals is:
👉 The system is excellent at intervention
👉 But weak at transformation
Not as a competitor to medicine…
But as the solution that comes next:
👉 The Off-Ramp
We are at a crossroads.
One path leads to:
The other leads to:
👉 Are we helping people live better… or just manage risk forever?
Cholesterol is not the enemy.
Food labels are not the solution.
Drugs are not the full answer.
👉 The future of health belongs to those who can restore metabolic function, rebuild lifestyle, and empower people to take control.